Avelumab First-Line Maintenance for Locally Advanced or Metastatic Urothelial Carcinoma: Results From the Real-World US PATRIOT-II Study
These results align with the JAVELIN Bladder 100 clinical trial and other real-world studies, supporting avelumab 1LM use in patients with la/mUC without progression following 1L PBC.
Authors
- Cora Nanette Sternberg (ORCID: https://orcid.org/0000-0003-3938-2627)
- Sarah Hanson (ORCID: https://orcid.org/0000-0003-1587-6999)
- Valerie Morris (ORCID: https://orcid.org/0000-0002-8105-585X)
- Chad Downey
- Shilpa Gupta (ORCID: https://orcid.org/0000-0002-8775-503X)
- Howard M. Katzenstein (ORCID: https://orcid.org/0000-0002-5314-2972)
- Petros D. Grivas (ORCID: https://orcid.org/0000-0003-3965-3394)
- Frank X. Liu (ORCID: https://orcid.org/0000-0001-7453-6922)
- Thomas Hutson
- Guru Sonpavde (ORCID: https://orcid.org/0000-0002-1010-9611)
- Jason Robert Brown (ORCID: https://orcid.org/0000-0001-6225-7555)
- Alicia C. Shillington (ORCID: https://orcid.org/0000-0003-2534-0960)
- Pedro Barata (ORCID: https://orcid.org/0000-0002-4537-5450)
- Melissa Kirker
- Vaidehi Dave (ORCID: https://orcid.org/0000-0003-2960-4599)
- Abhijeet Bhanegaonkar
- Helen Moon (ORCID: https://orcid.org/0009-0007-6303-5285)
Institutions
- Cleveland Clinic (US)
- Pfizer (United States) (US)
- University of Washington (US)
- Cornell University (US)
- Texas Oncology (US)
- Florida Hospital Cancer Institute (US)
- Fred Hutch Cancer Center (US)
- Ono Pharmaceutical (United States) (US)
- Kaiser Permanente Riverside Medical Center (US)
- University Hospitals Seidman Cancer Center (US)
- RTI Health Solutions (US)
- Epi-Q (United States) (US)
- Weill Cornell Medicine (US)
Publication Details
- Journal
- Clinical Genitourinary Cancer
- Published
- 2024-10-17
- DOI
- https://doi.org/10.1016/j.clgc.2024.102238
- Citations
- 14
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 8.02